GLP-1-话题@MedSci

#GLP-1#

114篇内容 | 4024人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1422772, encodeId=f7cb1422e7259, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, objectType=article, longId=300317, objectId=525d30031e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525d30031e63, replyNumber=0, likeNumber=105, createdTime=2022-03-10, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525d30031e63, moduleTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525d30031e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422771, encodeId=f2ab1422e7110, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况, objectType=article, longId=295500, objectId=4e5b295500be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5b295500be, replyNumber=0, likeNumber=94, createdTime=2022-02-13, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5b295500be, moduleTitle=BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5b295500be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422770, encodeId=8b941422e708a, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较, objectType=article, longId=295380, objectId=927829538021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=927829538021, replyNumber=0, likeNumber=91, createdTime=2022-02-11, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=927829538021, moduleTitle=JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=927829538021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽, objectType=article, longId=293924, objectId=e7922939240b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7922939240b, replyNumber=0, likeNumber=99, createdTime=2022-01-14, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7922939240b, moduleTitle=JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7922939240b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422768, encodeId=58cb1422e6841, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较, objectType=article, longId=220590, objectId=46c922059001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46c922059001, replyNumber=0, likeNumber=81, createdTime=2021-11-20, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46c922059001, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46c922059001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422767, encodeId=dfaa1422e674f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Antioxidants：GLP-1类似物利拉鲁肽通过减少氧化应激和炎症改善脓毒血症影响的血管功能, objectType=article, longId=220123, objectId=aaa52201239d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaa52201239d, replyNumber=0, likeNumber=88, createdTime=2021-11-12, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaa52201239d, moduleTitle=Antioxidants：GLP-1类似物利拉鲁肽通过减少氧化应激和炎症改善脓毒血症影响的血管功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaa52201239d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422766, encodeId=0fa21422e66a0, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析, objectType=article, longId=220003, objectId=76552200039d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76552200039d, replyNumber=0, likeNumber=80, createdTime=2021-11-10, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76552200039d, moduleTitle=Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76552200039d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422779, encodeId=71261422e79f4, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Mol Metab：GLP-1在阿尔茨海默病中通过促进有氧糖酵解，提高星形胶质细胞对神经元的支持能力, objectType=article, longId=291229, objectId=75c629122964, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75c629122964, replyNumber=0, likeNumber=72, createdTime=2021-11-10, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75c629122964, moduleTitle=Mol Metab：GLP-1在阿尔茨海默病中通过促进有氧糖酵解，提高星形胶质细胞对神经元的支持能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75c629122964)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422765, encodeId=9b531422e6529, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes Obes Metab：finerenone(非奈利酮)对GLP-1RA治疗慢性肾脏病和2型糖尿病患者的疗效和安全性, objectType=article, longId=219640, objectId=2997219640dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2997219640dc, replyNumber=0, likeNumber=88, createdTime=2021-11-03, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2997219640dc, moduleTitle=Diabetes Obes Metab：finerenone(非奈利酮)对GLP-1RA治疗慢性肾脏病和2型糖尿病患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2997219640dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422764, encodeId=47ae1422e6410, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, objectType=article, longId=218302, objectId=3ada21830258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ada21830258, replyNumber=0, likeNumber=50, createdTime=2021-10-11, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ada21830258, moduleTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ada21830258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422763, encodeId=9f7a1422e63d2, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响, objectType=article, longId=218049, objectId=35582180496e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35582180496e, replyNumber=0, likeNumber=97, createdTime=2021-10-04, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35582180496e, moduleTitle=Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35582180496e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422762, encodeId=86881422e6291, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益, objectType=article, longId=217820, objectId=f24821e820ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24821e820ef, replyNumber=0, likeNumber=72, createdTime=2021-09-30, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24821e820ef, moduleTitle=Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24821e820ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422761, encodeId=f86d1422e61aa, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率, objectType=article, longId=216263, objectId=a32e21626362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a32e21626362, replyNumber=0, likeNumber=94, createdTime=2021-08-26, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a32e21626362, moduleTitle=Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a32e21626362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平, objectType=article, longId=213906, objectId=58312139068b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58312139068b, replyNumber=0, likeNumber=86, createdTime=2021-07-09, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58312139068b, moduleTitle=Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58312139068b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422758, encodeId=10481422e586f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, objectType=article, longId=213591, objectId=78a9213591c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78a9213591c8, replyNumber=0, likeNumber=80, createdTime=2021-07-02, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78a9213591c8, moduleTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78a9213591c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究, objectType=article, longId=213502, objectId=ee6b2135028f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee6b2135028f, replyNumber=0, likeNumber=81, createdTime=2021-07-01, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee6b2135028f, moduleTitle=SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee6b2135028f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422757, encodeId=52141422e57fa, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes Care：“明星药”GLP-1 RA艾塞那肽对2型糖尿病患者颈动脉硬化的影响, objectType=article, longId=213293, objectId=30d2213293d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30d2213293d8, replyNumber=0, likeNumber=68, createdTime=2021-06-28, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30d2213293d8, moduleTitle=Diabetes Care：“明星药”GLP-1 RA艾塞那肽对2型糖尿病患者颈动脉硬化的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30d2213293d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422756, encodeId=dbe61422e562d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响, objectType=article, longId=213289, objectId=5cdb21328936, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cdb21328936, replyNumber=0, likeNumber=80, createdTime=2021-06-28, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cdb21328936, moduleTitle=Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cdb21328936)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422755, encodeId=a41f1422e55d5, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, objectType=article, longId=205766, objectId=c84a205e66fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a205e66fd, replyNumber=0, likeNumber=48, createdTime=2021-01-17, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a205e66fd, moduleTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84a205e66fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422754, encodeId=d60d1422e541a, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显, objectType=article, longId=203520, objectId=4ff9203520a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff9203520a1, replyNumber=0, likeNumber=46, createdTime=2020-11-20, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff9203520a1, moduleTitle=NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff9203520a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GLP-1

2020-05-29

yibei (审核中...)

前往app查看评论内容

#GLP-1#

JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系

2022-03-10

yibei (审核中...)

前往app查看评论内容

#GLP-1#

BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况

2022-02-13

yibei (审核中...)

前往app查看评论内容

#GLP-1#

JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较

2022-02-11

yibei (审核中...)

前往app查看评论内容

#GLP-1#

JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽

2022-01-14

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较

2021-11-20

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Antioxidants：GLP-1类似物利拉鲁肽通过减少氧化应激和炎症改善脓毒血症影响的血管功能

2021-11-12

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析

2021-11-10

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Mol Metab：GLP-1在阿尔茨海默病中通过促进有氧糖酵解，提高星形胶质细胞对神经元的支持能力

2021-11-10

柳叶一刀 (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes Obes Metab：finerenone(非奈利酮)对GLP-1RA治疗慢性肾脏病和2型糖尿病患者的疗效和安全性

2021-11-03

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关

2021-10-11

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Ann Intern Med：SGLT2抑制剂 vs GLP-1 RA对有无CVD的T2D患者心血管事件风险的影响

2021-10-04

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益

2021-09-30

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率

2021-08-26

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平

2021-07-09

yibei (审核中...)

前往app查看评论内容

#GLP-1#

NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用

2021-07-02

yibei (审核中...)

前往app查看评论内容

#GLP-1#

SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究

2021-07-01

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes Care：“明星药”GLP-1 RA艾塞那肽对2型糖尿病患者颈动脉硬化的影响

2021-06-28

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响

2021-06-28

yibei (审核中...)

前往app查看评论内容

#GLP-1#

BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势

2021-01-17

yibei (审核中...)

前往app查看评论内容

#GLP-1#

NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显

2020-11-20

科室
- - 订阅+
  - 更多科室
工具
服务